Ashraf-Uz-Zaman, Md. published the artcileDesign, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer, COA of Formula: C13H9ClO2, the main research area is structure preparation urea compound FGFR1 inhibitor metastatic breast cancer; Blood-brain-barrier; FGFR1; In silico; Neurotoxicity; Synthesis; Triple-negative breast cancer.
Triple-neg. breast cancer (TNBC) is an aggressive type of cancer characterized by higher metastatic and reoccurrence rates, where approx. one-third of TNBC patients suffer from the metastasis in the brain. At the same time, TNBC shows good responses to chemotherapy, a feature that fuels the search for novel compounds with therapeutic potential in this area. Recently, we have identified novel urea-based compounds with cytotoxicity against selected cell lines and with the ability to cross the blood-brain barrier in vivo. We have synthesized and analyzed a library of more than 40 compounds to elucidate the key features responsible for the observed activity. We have also identified FGFR1 as a mol. target that is affected by the presence of these compounds, confirming our data using in silico model. Overall, we envision that these compounds can be further developed for the potential treatment of metastatic breast cancer.
European Journal of Medicinal Chemistry published new progress about Antitumor agents. 61343-99-5 belongs to class chlorides-buliding-blocks, name is 4-(4-Chlorophenoxy)benzaldehyde, and the molecular formula is C13H9ClO2, COA of Formula: C13H9ClO2.
Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics